SAN DIEGO--(BUSINESS WIRE)--Stemedica Cell Technologies, Inc, (“Stemedica”), a leading manufacturer of best-in-class adult stem cells, has entered into a Collaboration Agreement with Lumenis, Ltd. (“Lumenis”), a global leader in medical laser technology. This collaboration agreement will focus on the implementation of a first-of-its-kind, comprehensive clinical study for the treatment of macular degeneration using Stemedica’s MCT™ (Multiple Cell Technology) adult stem cells and the Lumenis SRT™ Laser. The clinical study will be conducted at the Fyodorov Eye Institute in Moscow, Russia. The Institute was founded in the 1960’s by the late Dr. Svyatoslav Fyodorov and is regarded as a global leader in treating ocular diseases. Over the past twenty years alone the Institute has treated over 12.5 million patients. A parallel study will take place at Hospital Angeles, a state-of-the-art hospital located in Tijuana, Mexico. The clinical studies at both Fyodorov Eye Institute and Hospital Angeles will focus on combining stem cell therapy with the use of the Lumenis SRT™ laser to treat macular degeneration.
